Torrent Pharma Q4 Review - In-Line Numbers; Focus On Margins, Brands To Sustain: ICICI Direct
Newly compressed tablets fall into a container. (Photographer Mikael Sjoberg/Bloomberg)

Torrent Pharma Q4 Review - In-Line Numbers; Focus On Margins, Brands To Sustain: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Torrent Pharmaceuticals Ltd.'s Q4 FY21 topline remained subdued with growth in India and Germany offset by decline in U.S. sales.

Revenues stayed flattish, down 0.5% YoY to Rs 1937 crore mainly due to 30.1% YoY decline in U.S. formulations to Rs 269 crore.

Domestic sales grew 9.8% YoY to Rs 922 crore.

Brazil de-grew 3.6% YoY to Rs 189 crore. Germany business grew a robust 23.6% YoY to Rs 267 crore.

Ebitda margins expanded 189 basis points YoY to 30.0% mainly led by better gross margin performance.

Subsequently, Ebitda grew 6.2% YoY to Rs 582 crore.

Profit after tax grew 3.2% YoY to Rs 324 crore.

Click on the attachment to read the full report:

ICICI Direct Torrent Pharma Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.